MediciNova Company Profile

05:10 EDT 20th June 2018 | BioPortfolio

MediciNova, Inc. is a development-stage biopharmaceutical company focused on acquiring, developing and commercializing high-quality small molecule therapeutics. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova has built a diversified portfolio of drug candidates each of which we believe has broad patent protection, a well-characterized and differentiated therapeutic profile and attractive commercial potential. MediciNova currently has eight compounds in clinical development for ten different indications representing large market opportunities. Medicinova’s pipeline includes treatments for asthma, Generalized Anxiety Disorder, interstitial cystitis, multiple sclerosis, status asthmaticus, preterm labor, cancer, urinary incontinence and thrombotic disorders. Several of these programs are in advanced clinical testing MediciNova’s strategy is to advance its clinical programs through the Phase II proof-of-concept stage and, at appropriate points of high-value inflection, to establish strategic alliances and partnerships to support Phase III clinical testing and commercialization of selected development programs. MediciNova may also retain certain promising compounds for further in-house development and potential commercialization. MediciNova’s executive management team has extensive global development, regulatory and commercial experience, and manages its international clinical and manufacturing operations through efficient and cost-effective utilization of contract research organizations. Headquartered in San Diego, California, MediciNova today has 24 employees.


4350 La Jolla Village Drive
Suite 950
San Diego
United States of America


Phone: (858) 373-1500
Fax: (858) 373-7000

News Articles [51 Associated News Articles listed on BioPortfolio]

MediciNova and UCLA to conduct trial of MN-166 for AUD

MediciNova, in partnership with researchers at the University of California, Los Angeles (UCLA), US, is set to begin a clinical...Read More... The post MediciNova and UCLA to conduct trial of MN-166 f...

MediciNova's IND for glioblastoma approved by FDA

MediciNova's investigative new drug application for MN-166, or ibudilast, in combination with chemotherapy agent temozolomide -More- 

MediciNova’s Drug Flunks Phase II Trial

MediciNova announced that its Phase II clinical trial of ibudilast (MN-166) failed to meet its primary endpoint for methamphetamine dependence.

MediciNova Halts Trial Early Following Positive Interim Analysis

Investors in La Jolla, Calif.-based MediciNova are celebrating this morning as company shares are up more than 18 percent following the early completion of a mid-stage non-alcoholic steatohepatitis tr...

Active-Investors: Blog Exposure - MediciNova's MN-166 Shows Reduction in Confirmed Disability Progression in SPRINT-MS Phase-2b Trial

Stock Monitor: Pacific Biosciences of California Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 05, 2018 / has just released a free research report on MediciNova, I...

MediciNova’s MN-001 meets primary end point in NASH / NAFLD study

MediciNova said its MN-001 (tipelukast) has met its primary endpoint of reducing mean serum triglycerides in the phase 2 clinical trial of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty ...

MediciNova (MNOV) Reaches New 12-Month High at $13.98

Shares of MediciNova, Inc. reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $13.98 and last traded at $13.97, with a volume of 300897 shares traded.

Active-Investors: Wired News - MediciNova Released Results of Phase-2 Clinical Trial Assessing MN-166 (ibudilast) in Methamphetamine Dependence

Stock Monitor: AC Immune Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 03, 2018 / has just released a free research report on MediciNova, Inc. (NASDAQ: MNOV). If you ...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [1 Associated Companies listed on BioPortfolio]


MediciNova, Inc. is a development-stage biopharmaceutical company focused on acquiring, developing and commercializing high-quality small molecule therapeutics. Through strategic alliances primarily ...

More Information about "MediciNova" on BioPortfolio

We have published hundreds of MediciNova news stories on BioPortfolio along with dozens of MediciNova Clinical Trials and PubMed Articles about MediciNova for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of MediciNova Companies in our database. You can also find out about relevant MediciNova Drugs and Medications on this site too.

Quick Search


Relevant Topics

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Corporate Database Quicklinks

Searches Linking to this Company Record